Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April …
Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019
NEW YORK and LONDON, July 31, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat …
Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering
NEW YORK and LONDON, June 28, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
[Read more...] about Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering
Change of AGM Venue on June 27, 2019
Dear Shareholder, We would like to inform shareholders that we shall be unable to hold our forthcoming Annual General Meeting at the place stated in the …
Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)
Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events. Improvement in …
